The
Refractive Ocular Surface
ASCRS respondents see an average of 30
patients
per month with ocular surface disease
requiring treatment beyond artificial tears.
When asked about the Delphi/DEWS guidelines
for treating aqueous deficient dry eye and MGD,
more than a third (34%) of respondents were
unaware of the Delphi/DEWS guidelines, and
38% think they follow the guidelines but are
uncertain.
Nearly half of ASCRS respondents' patients are
thought to have meibomian gland dysfunction
(MGD) and roughly 35% have aqueous deficient
dry eye (ADDE). Cyclosporine is used as a
primary therapy in patients with moderate dry
eye; U.S. physicians are significantly more
likely than non-U.S. physicians to prescribe
this therapy.
Respondents report that an average of 20% of
their cataract surgery patients present for their
preoperative consult with sufficient OSD that
requires some treatment beyond artificial
tears. Additionally, an average of 23% of
ASCRS respondents' cataract surgery patients
present as asymptomatic of any OSD prior to
surgery but develop symptoms postop.
ASCRS 2016 Clinical Survey
4
